About this trial

From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

Eligibility criteria

Qualifiers

Diagnosis of ITP, AIHA, Evans Syndrome

Onset before the age of 18

Disqualifiers

Opposition of legal representative or to data collection

Trial design

Treatments tested in this trial

  • data collection

Treatment groups

3,500 Participants
are divided into 3 treatment groups

Locations

9
CHU Amiens Picardie Service d' Onco-Immuno-Hématologie Pédiatrique Amiens France
CHU d'Angers Unité d'Hémato-Oncologie Pédiatrique Angers France
BESANCON CHU de Besançon Hôpital Jean MINJOZ Unité d'Hémato-Oncologie Pédiatrique, Pédiatrie 1 Besançon France
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique Bordeaux France

Sponsors and collaborators

University Hospital, Bordeaux

Lead sponsor